Page 55 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

67. Wong WJ, Liu HC, Fuh JL, Wang SJ, Hsu LC, Wang PN, et al. A double-blind, placebo-
controlled study of tacrine in Chinese patients with Alzheimer's disease. Dement Geriatr
Cogn Disord 1999;10(4):289-94.
68. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week
randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The
Tacrine Study Group. JAMA 1994;271(13):985-91.
69. Wood PC, Castleden CM. A double-blind, placebo controlled, multicentre study of tacrine
for Alzheimer's disease. INT J GERIATR PSYCHIATRY 1994;9(8):649-654.
70. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev
2005(2):CD003154.
71. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil
on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int
Psychogeriatr 2002;14(4):389-404.
72. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Functional, cognitive and
behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res
Opin 2002;18(6):347-54.
73. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, et al. Efficacy of donepezil
on maintenance of activities of daily living in patients with moderate to severe Alzheimer's
disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51(6):737-44.
74. Potkin SG, Anand R, Hartman R, Veach J, Grossberg G. Impact of Alzheimer's disease and
rivastigmine treatment on activities of daily living over the course of mild to moderately
severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(4):713-20.
75. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe
Alzheimer's disease. Int J Geriatr Psychiatry 2004;19(3):243-9.
76. Rive B, Vercelletto M, Damier FD, Cochran J, Francois C. Memantine enhances autonomy
in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19(5):458-64.
77. Doody R, Wirth Y, Schmitt F, Mobius HJ. Specific functional effects of memantine
treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn
Disord 2004;18(2):227-32.
78. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in
Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75(5):677-85.
79. Burback D, Molnar FJ, St John P, Man-Son-Hing M. Key methodological features of
randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important
difference, sample size and trial duration. Dement Geriatr Cogn Disord 1999;10(6):534-40.
80. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of
tacrine administration in patients with Alzheimer's disease. JAMA 1994;271(13):992-8.
81. Cutler NR, Sramek JJ. Tolerability profiles of AChEIs: a critical component of care for
Alzheimer's disease patients. International Journal of Geriatric Psychopharmacology
1998;1(Suppl 1):S20-S25.
82. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease:
epidemiology and management. Drugs Aging 2001;18(11):853-62.
83. Gillette-Guyonnet S, Cortes F, Cantet C, Vellas B. Long-term cholinergic treatment is not
associated with greater risk of weight loss during Alzheimer's disease: data from the French
REAL.FR cohort. J Nutr Health Aging 2005;9(2):69-73.
84. Dunn NR, Pearce GL, Shakir SA. Adverse effects associated with the use of donepezil in
general practice in England. J Psychopharmacol 2000;14(4):406-8.

Alzheimer's Drugs Page 55 of 205